Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis

Launched by UNIVERSITY HOSPITAL, BORDEAUX · Mar 11, 2021

Keywords

ClinConnect Summary

This clinical trial is looking into a condition called immune thrombocytopenia (ITP), which is when a person's blood has a low number of platelets due to the immune system mistakenly attacking them. The researchers aim to understand if certain antibodies—proteins that the immune system produces—can help identify whether a patient’s low platelet count is related to ITP at the time of diagnosis. Currently, these antibodies are not commonly used for diagnosing ITP, and this study will help explore their potential role.

To participate in this trial, individuals must be over 18 years old and have a platelet count below 100,000 per microliter of blood, confirmed by tests. Importantly, they should not have started any treatment for their condition yet. Participants will contribute to important research that may improve how ITP is diagnosed and understood. If you think you may be eligible and are interested in joining, you can find more information and discuss it with a healthcare provider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient over 18 years old;
• • Patients with thrombocytopenia \<100 G/L, checked twice, having ruled out false thrombocytopenia by platelet aggregation and acute leukemia by smear;
• • No treatment started;
• • Free, informed and written consent signed by the participant and the investigator (no later than the day of inclusion and prior to any review required by the research);
• • Person affiliated or benefiting from a social security scheme.
• Exclusion Criteria:
• • Secondary ITP;
• • False thrombocytopenia;
• • Patients who have been transfused with platelets for less than 7 days with efficacy;
• • Patient treated for thrombocytopenia (48 hours of corticosteroid therapy is tolerated and is not an exclusion criteria);
• • Patient with acute leukemia;
• • Pregnant or breastfeeding woman;
• • False thrombocytopenia;
• • Patient under guardianship, curatorship or any other legal protection regime.